Methoxsalen Macopharma (Methoxsalen)

Methoxsalen intercalates into DNA and, after UVA exposure, creates covalent cross‑links with pyrimidine bases. These cross‑links block DNA replication and cell division, reducing the proliferation of diseased skin cells and facilitating therapeutic outcomes in photosensitive treatments.

The dosage of Methoxsalen Macopharma is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the specific indication, patient skin type, and response to UVA therapy. Patients should follow the prescribing clinician’s instructions precisely.

The safety of methoxsalen in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential therapeutic benefit justifies the possible risk to the fetus or infant. Healthcare providers should discuss alternatives and risk assessment with the patient.

To request Methoxsalen Macopharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methoxsalen is a psoralen, distinct from non‑psoralen phototherapy agents such as narrow‑band UVB. While both aim to modulate skin disease, methoxsalen requires oral or extracorporeal administration combined with UVA (PUVA), offering deeper penetration but a higher risk of photosensitivity compared with UVB alone.

Methoxsalen Macopharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Methoxsalen Macopharma is supplied for extracorporeal use, meaning it is administered under controlled clinical conditions, often as an oral dose taken prior to a scheduled UVA exposure session. The exact administration protocol is defined by the treating physician.

Serious risks include severe phototoxic reactions such as blistering and ulceration, hepatotoxicity indicated by elevated liver enzymes, and rare hematologic effects like aplastic anemia. Patients should be monitored closely for any signs of these adverse events during treatment.

Methoxsalen is contraindicated in individuals with known hypersensitivity to psoralens, active skin infections, uncontrolled liver disease, or those taking medications that markedly increase photosensitivity. Pregnant or breastfeeding women should avoid it unless clearly indicated by a healthcare professional.